Rheumatologists report largely adhering to American College of Rheumatology guidelines for gout management, but show notable ...

febuxostat 120-mg, and allopurinol groups, respectively. Serious adverse events were reported by 161 patients, with cardiac disorders being reported most frequently by 48 patients, all of whom had ...

Febuxostat 40 mg daily appears to be as efficacious as allopurinol in lowering serum uric acid levels. [38] Both febuxostat 40 and 80 mg can be given to patients with mild-to-moderate renal impair ...

however 3 to 5% of patients cannot tolerate allopurinol. An alternative XOI, Febuxostat, launched in the US in 2009 with the hope of treating allopurinol intolerant patients, however while Febuxostat ...

An alternative XOI, Febuxostat, launched in the US in 2009 with the hope of treating allopurinol intolerant patients, however while Febuxostat achieved peak sales of approximately US$450 million2 ...

The journey of Takeda’s gout med Uloric—which turned rocky in recent years—has come to an end in the U.S. | Following some ...

Current first-line therapies like allopurinol and febuxostat can be very effective, but some patients – roughly 1% according to FDA estimates – don’t get the hoped-for benefit, while others ...

Objectives To update comparative CV safety of febuxostat versus allopurinol among patients with gout Methods Using the 2011-2019 Korea National Health Insurance database, we conducted a cohort study ...

The goal of treatment is to reduce levels of uric acid in the blood below the 6 mg/dl threshold, but in some cases, current drugs like allopurinol and febuxostat aren’t able to achieve that ...